Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Pediatric experts from Le Bonheur’s Heart Institute and the University of Tennessee Health Science Center will present lectures, posters, abstracts and hands-on workshops. Pediatric experts from Le ...

Credit: Getty Images. Evidence suggests that patent ductus arteriosus comprises anywhere from 5% to 10% of all congenital heart disease. Although the majority of congenital heart diseases (CHD) are ...

Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...

Patent ductus arteriosus (PDA) is a congenital cardiac defect that occurs when the ductus arteriosus fails to close. The result is a persistent communication between the aorta and pulmonary artery, ...

Patent ductus arteriosus (PDA), one of the more common cardiac defects present at birth, is the persistence of an opening between the pulmonary artery and aorta. This opening is as a result of failure ...

Abbott (NYSE: ABT) received FDA clearance for its Amplatzer Piccolo delivery system for use with the Amplatzer Piccolo ...

As babies make the transition of depending on the mother for oxygen and depending on their own lungs during birth, an arterial connection has to close on its own. Normally this transition occurs ...

SHOULD closure of a patent ductus arteriosus with reversal of flow be attempted? If so, how can the high surgical mortality hitherto reported 1–3 be reduced? An attempt is made to answer these ...